68
Ga-PSMA-11 positron emission computed tomography /computed tomography (PET/CT) is more sensitive than magnetic resonance imaging (MRI) in detecting prostate cancer (PCa). We evaluated the value of
68
Ga-PSMA-11 PET/CT with MRI in treatment-naive PCa.
This retrospective study was approved by the hospital ethics committee. The MRI and
68
Ga-PSMA-11 PET/CT imaging data of 63 cases of highly suspected PCa were enrolled in this study. The SUV
max
and apparent diffusion coefficient (ADC), and their ratio, were assessed as diagnostic markers to distinguish PCa from benign disease.
There were 107 prostate lesions detected in 63 cases. Forty cases with 64 malignant primary lesions were confirmed PCa, whereas 23 cases had 43 benign lesions. PSMA-avid lesions correlated with hypointense signal on ADC maps and hyperintense signal on diffusion-weighted imaging. The ADC of PCa was lower than that of benign lesions, and SUV
max
and SUV
max
/ADC of PCa was higher than that of benign lesions (
P
< .01). ADC had significant negative correlation with Gleason score (GS) and SUV
max
, SUV
max
, and SUV
max
/ADC positively correlated with GS. From ROC analysis, we established cutoff values of ADC, SUV
max
, and SUV
max
/ADC at 1.02 × 10
−3
mm
2
/s, 11.72, and 12.35, respectively, to differentiate PCa from benign lesions. The sensitivity, specificity, and AUC were 90.6%, 58.1%, and 0.816 for ADC, 67.2%, 97.7%, and 0.905 for SUV
max
, and 81.2%, 88.4%, and 0.929 for SUV
max
/ADC, respectively.
68
Ga-PSMA-11 PET/CT combined with MRI offers higher diagnostic efficacy in the detection of PCa than either modality alone.